PsyBio Therapeutics Corp. (PSYBF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.43 Million | -6.94 Million | -863.76 Thousand | -24.13 Thousand | -13.91 Thousand | -39.71 Thousand |
| Net Income | -4.88 Million | -11.01 Million | -6.43 Million | -16.15 Thousand | -20.86 Thousand | -39.85 Thousand |
| Depreciation & Amortization | 152.08 Thousand | - | - | - | - | - |
| Deferred income taxes | 156.28 Thousand | - | - | - | - | - |
| Stock-based compensation | 508.7 Thousand | 2.12 Million | 3.85 Million | - | - | - |
| Change in working capital | 610.91 Thousand | 667.92 Thousand | 527.13 Thousand | -30.78 Thousand | 6947.01 | -7081.99 |
| Other non-cash items | 21.05 Thousand | 1.27 Million | 1.19 Million | 22.81 Thousand | -0.01 | 7221.86 |
| Investing Cash Flow | 3.52 Million | -3.56 Million | - | - | - | - |
| Investments in PPE | -0.37 | 3739.81 | - | - | - | - |
| Acquisitions | - | 175.76 Thousand | - | - | - | - |
| Investment purchases | -350.03 Thousand | -8.16 Million | - | - | - | - |
| Sales/Maturities of investments | 3.87 Million | 4.42 Million | - | - | - | - |
| Other Investing Activities | 3524.43 | -3739.81 | - | - | - | - |
| Financing Cash Flow | -54.97 Thousand | 10.36 Million | 1.15 Million | - | - | -5549.43 |
| Debt repayment | -123.28 Thousand | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -88.1 Thousand | - | - | - | - | - |
| Common Stock Issuance | 156.41 Thousand | 11.27 Million | - | - | - | -5549.43 |
| Other Financing Activities | 156.41 | -907.55 Thousand | 1.15 Million | - | - | - |
| Accounts receivables | - | 13.81 Thousand | - | - | - | - |
| Accounts payables | 843.66 Thousand | 489.28 Thousand | - | - | - | - |
| Inventory | - | 14.81 Thousand | - | - | - | - |
| Other working capital | -232.75 Thousand | 150 Thousand | 527.13 Thousand | -30.78 Thousand | 6947.01 | -7081.99 |
| Cash at beginning of period | 124.39 Thousand | 269.7 Thousand | -293.92 Thousand | 193.54 Thousand | 206.08 Thousand | 254.15 Thousand |
| Cash at end of period | 157.25 Thousand | 124.39 Thousand | 294.22 | 161.56 Thousand | 193.54 Thousand | 206.08 Thousand |
| Capital Expenditure | -0.37 | 3739.81 | - | - | - | - |
| Effect of forex changes on cash | 445.00 | 495.00 | - | - | - | - |
| Net cash flow / Change in cash | 32.86 Thousand | -145.3 Thousand | 294.21 Thousand | -31.98 Thousand | -12.54 Thousand | -48.06 Thousand |
| Free Cash Flow | -3.43 Million | -6.94 Million | -863.76 Thousand | -24.13 Thousand | -13.91 Thousand | -39.71 Thousand |
| Breakdown | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 | 2022 Q3 | 2022 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -144.68 Thousand | -811.49 Thousand | -4.88 Million | -941.64 Thousand | -921.89 Thousand | -1.43 Million |
| Depreciation & Amortization | - | 38.02 Thousand | 152.08 Thousand | 38.01 Thousand | 38.02 Thousand | 38.02 Thousand |
| Deferred income taxes | - | - | 156.28 Thousand | - | -3593.00 | 59.05 Thousand |
| Stock-based compensation | 260.00 | 219.96 Thousand | 508.7 Thousand | 2277.00 | 83.96 Thousand | 148.25 Thousand |
| Change in working capital | -210.51 Thousand | 194.62 Thousand | 610.91 Thousand | 730.93 Thousand | 90.18 Thousand | -118.83 Thousand |
| Other non-cash items | 694.53 Thousand | 3392.00 | 21.05 Thousand | 4432.00 | 5429.00 | 6399.00 |
| Investing Cash Flow | 622.00 | - | 3.52 Million | 48.99 Thousand | 856.73 Thousand | 1.37 Million |
| Investments in PPE | 0.94 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -350.03 Thousand | -4865.80 | -2844.76 | -1398.26 |
| Sales/Maturities of investments | - | - | 3.87 Million | 53.85 Thousand | 856.73 Thousand | 1.37 Million |
| Other Investing Activities | 622.00 | - | 3524.43 | 0.80 | 2844.76 | 1398.26 |
| Financing Cash Flow | 558.7 Thousand | 290.82 Thousand | -54.97 Thousand | 142.71 Thousand | -27.39 Thousand | -124.27 Thousand |
| Debt repayment | - | - | -123.28 Thousand | -13.69 Thousand | -27.39 Thousand | -41.09 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -88.1 Thousand | -1224.70 | -7000.00 | -83.18 Thousand |
| Common Stock Issuance | 244.47 Thousand | 294 Thousand | 156.41 Thousand | 156.41 Thousand | - | - |
| Other Financing Activities | 314.23 Thousand | -3175.00 | 156.41 | 1224.70 | 7000.00 | -7.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | 843.66 Thousand | 680.48 Thousand | 97.62 Thousand | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -210.51 Thousand | 194.62 Thousand | -232.75 Thousand | 50.45 Thousand | -7443.00 | -118.83 Thousand |
| Cash at beginning of period | 91.93 Thousand | 157.25 Thousand | 124.39 Thousand | 180.64 Thousand | 58.68 Thousand | 108.49 Thousand |
| Cash at end of period | 42.78 Thousand | 91.93 Thousand | 157.25 Thousand | 157.25 Thousand | 180.64 Thousand | 58.68 Thousand |
| Capital Expenditure | 0.94 | - | - | - | - | - |
| Effect of forex changes on cash | 670.00 | -670.00 | 445.00 | -114.00 | 514.00 | 174.00 |
| Net cash flow / Change in cash | -49.15 Thousand | -65.32 Thousand | 32.86 Thousand | -23.38 Thousand | 121.95 Thousand | -49.81 Thousand |
| Free Cash Flow | 339.6 Thousand | -355.48 Thousand | -3.43 Million | -165.98 Thousand | -707.89 Thousand | -1.3 Million |
DVYSR
1798
3630
NCLIND
ALTX
AVCRF